REFRACTORY MARGINAL ZONE LYMPHOMA
Clinical trials for REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blood cancer patients after CAR t fails
Disease control CompletedThis study tested a drug called nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow …
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New combo tackles tough lymphoma in early trial
Disease control CompletedThis early-phase study tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:04 UTC